Article

Men with low PSA may not need annual screening

Orlando, FL-A new analysis of data from the National Cancer Institute'snationwide Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screeningtrial suggests that annual PSA screening may not be necessary for many men.

Related Videos
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Patient talking with doctor | Image Credit: © bongkarn - stock.adobe.com
Shaya Taghechian, MD, answers a question during a video interview
doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
Raveen Syan, MD, FPMRS, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Cassandra K. Kisby, MD, MS, answers a question during a Zoom video interview
Vikas Desai, MD, answers a question during a Zoom video interview
Bree Duncan, RN, BSN, answers a question during a Zoom video interview
Related Content
Data show short-term benefit of certain hormonal treatments for GSM
September 10th 2024

Data show short-term benefit of certain hormonal treatments for GSM

Hannah Clarke
Data showed that vaginal estrogen, vaginal DHEA, oral ospemifene, and vaginal moisturizers may provide benefit in the management of symptoms related to GSM.
Speaking of Urology: Dr. Winter on the use of vaginal estrogen
July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff
In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.
Topical sildenafil cream found safe, tolerable in female sexual arousal disorder
August 27th 2024

Topical sildenafil cream found safe, tolerable in female sexual arousal disorder

Hannah Clarke
There were no differences in the number of treatment-related TEAEs in patients who received sildenafil cream vs patients who received placebo.
Dr. Malik evaluates quality of Reddit content on recurrent UTIs
March 17th 2022

Dr. Malik evaluates quality of Reddit content on recurrent UTIs

Urology Times staff
“I think we as urologists have to be proactive in providing information to our patients so that they avoid financial harm and potentially bodily harm from this sort of misinformation,” says Rena D. Malik, MD.
FDA approves cefepime/enmetazobactam for complicated UTI
February 27th 2024

FDA approves cefepime/enmetazobactam for complicated UTI

Hannah Clarke
The FDA approval is supported by data from the phase 3 ALLIUM trial, which demonstrated the non-inferiority and superiority of cefepime/enmetazobactam vs piperacillin/tazobactam.
Information and Guidance on the Adoption of Surgical Innovation and Technology in Urogynecology
February 24th 2024

Information and Guidance on the Adoption of Surgical Innovation and Technology in Urogynecology

American Urogynecologic Society
The aim of this document is to present a framework by which AUGS and its members can address the development of new technology and techniques, particularly in the surgical arena.
© 2024 MJH Life Sciences

All rights reserved.